Sino Biopharmaceutical's Asset Portfolio Offers Licensing Potential -- Market Talk

Dow Jones05-21 16:51

0851 GMT - Sino Biopharmaceutical's asset portfolio carries significant out-licensing potential, says its bull at DBS Group Research. The analysts estimate the Chinese pharmaceutical company could unlock $7.6 billion in value from three of its assets. It has a proven track record for such transactions, including with France's Sanofi in March. The analysts expect 2026-2028 earnings to expand by a 15% compound annual growth rate. Coupled with its strong financial position, Sino Biopharmaceutical could develop more assets that can be out-licensed in the future. DBS reinstates coverage with a buy rating and HK$6.50 target price. Shares closed 2.1% higher at HK$5.28. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

May 21, 2026 04:51 ET (08:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment